ArticleDose-response : a publication of International Hormesis Society
Prognostic Role of IL-18 in Various Human Cancers and Radiation Injuries: A Meta-Analysis.
Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026Review
- Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy.Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Review
- Transcriptomic profiling of peripheral blood cells in HPV-associated carcinoma patients receiving combined valproic acid and avelumab.Molecular oncology · 2024Article
- Effects of Corchorusoside C on NF-κB and PARP-1 Molecular Targets and Toxicity Profile in Zebrafish.International journal of molecular sciences · 2022Article
- Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression.Biomedicines · 2022Review
- Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, more and more studies have shown that various inflammatory factors have predictive effects on the prognosis of various human tumors. However, the prognostic role of interleukin 18 (IL-18) remains controversial. Furthermore, its role in radiation-induced injuries relating to radiotherapy (RT) is also unclear. In this study, we conducted the meta-analysis to clarify its roles in prognosis of human tumors and radiation-induced injuries relating to RT.
methodsWe comprehensively searched PubMed, Embase, and Cochrane Library to identify studies published before November 2019 involving patients with cancer expressing IL-18 and which reported overall survival (OS) during the follow-up period.
resultsA total of 1376 samples from 16 studies showed that high expression of IL-18 is closely related to prognosis and OS for patients with carcinoma (hazard ratio [HR]: 2.12; 95% CI: 1.81-2.49;
conclusionsHigh expression of IL-18 is related with poor prognosis of carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.